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IntroductIon
Over 90% percent of all U.S. feedlots over 1,000 
cattle capacity include an ionophore as part of their 
nutritional management program (USDA, 2011). 
Ionophores fed to feedlot cattle promote the efficient 
use of feedstuffs through improved rumen fermenta-
tion efficiency by altering the end products available 
for absorption and metabolism and, therefore, can re-
duce the cost of beef production by improving animal 
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ABSTRACT: The objective of this research was to use 
data from multiple studies to comprehensively quantify 
the effects of feeding 1) laidlomycin propionate (LP), 
alone and/or in combination with chlortetracycline, 
compared with 2) monensin sodium (MS), alone and/or 
in combination with tylosin, at commercially approved 
dosages, on ADG, DMI, feed efficiency (FE), mortality, 
and carcass characteristics (HCW and liver abscesses). 
A secondary objective was to explore potential sources 
of heterogeneity among the comparative effectiveness 
studies. A systematic review of peer-reviewed litera-
ture and industry reports was used to identify studies 
that included direct comparisons of these treatments 
in finishing steers in North America. Random-effects 
meta-analysis models of performance, carcass, and 
health-related outcomes were fitted with extracted data, 
consisting of a total of 17 data sets comprising a total of 
135 pens and 13,603 steers. Results showed that pens 
of steers fed LP had increased ADG (live and carcass 
adjusted), DMI, and HCW compared with those fed 
monensin (P < 0.05). However, liver abscesses were 
more common in LP-fed cattle than in MS-fed cattle 
(P < 0.05), presumably because of differences in the 
concurrently fed antimicrobials. No significant effects 
(P > 0.05) were identified for FE or for health-related 
outcomes (overall and cause-specific mortality). There 
was a substantial amount of heterogeneity in out-
comes among studies, and when pen size and type of 
production setting were included in mixed-effects meta-
regression models, they accounted for only a small 
proportion of the between-study heterogeneity found in 
the meta-analysis models. Therefore, caution should be 
exercised when interpreting summary estimates in the 
presence of substantial heterogeneity. However, these 
results provide comprehensive information on the com-
parative effects of different ionophores across multiple 
studies and multiple years, states, and production set-
tings. These unique results can enable quantitative and 
informed decisions by potential end users of these feed 
additives that are widely used in the U.S. beef indus-
try for reducing the costs of beef production through 
enhanced cattle performance.
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growth and feed efficiency (Russel and Strobel, 1989; 
Birkelo, 2003; Callaway et al., 2003; USDA, 2011). The 
efficacy of ionophores for improving cattle performance 
outcomes has been well documented in numerous stud-
ies (reviewed in Vogel, 1995; Birkelo, 2003). In fact, the 
efficacy of monensin in beef cattle was recently evalu-
ated using an extensive meta-analysis of data from 40 
peer-reviewed articles and 24 trial reports (Duffield et al., 
2012). However, similar analyses of data from compara-
tive effectiveness studies—those that directly compare 
the effectiveness of using different ionophore products 
in a feedlot setting—have not been previously reported.
There has been an increased emphasis on the use 
of meta-analysis in the animal science and veterinary 
literature as an important tool to synthesize treatment 
effects across multiple studies, particularly when bio-
logically or economically important effects may be 
difficult to detect without large sample sizes (Donner 
et al., 2001; Duffield et al., 2012). Complementary 
techniques such as meta-regression (O’Connor et al., 
2014b) can be used to identify factors associated with 
heterogeneity of responses across studies, and system-
atic reviews and bias assessments can be used to as-
sure that a repeatable approach is used for inclusion of 
studies (Duffield et al., 2012; O’Connor et al., 2014a). 
The primary objective of this systematic review and 
meta-analyses was to determine the effects of feeding 
laidlomycin propionate (LP), alone and/or in combi-
nation with chlortetracycline, compared with feeding 
monensin sodium (MS), alone and/or in combination 
with tylosin, at commercially approved dosages, on 
feed efficiency (FE), ADG, DMI, mortality, liver ab-
scesses, and HCW of finishing steers in North America.
MATeRiAlS ANd MeThodS
Systematic Review of the Literature
The original research question was formulated 
as: What are the effects of LP (Cattlyst; Zoetis LLC, 
Florham Park, NJ), fed alone and/or in combination 
with chlortetracycline (Aureomycin; Zoetis LLC), 
compared with MS (Rumensin; Elanco Animal Health, 
Indianapolis, IN), fed alone and/or in combination with 
tylosin (Tylan; Elanco Animal Health), at commercial-
ly approved dosages, on performance (ADG, FE, and 
DMI), health (cause-specific and overall mortality), and 
carcass characteristics (HCW and liver abscesses) of 
finishing steers in North America in studies that have a 
randomized control trial design?
The research question comprised 4 main compo-
nents: 1) population (finishing steers), 2) interventions 
(LP and MS alone or in combination with chlortetracy-
cline and tylosin, respectively), 3) outcomes (ADG, DMI, 
FE, HCW, mortality, and liver abscesses), and 4) study 
design (randomized controlled trial [rct] designs). To 
generate a complete list of all primary research that could 
answer our research question, search terms were cre-
ated to account for these components. The actual search 
terms and Boolean expressions used or the format var-
ied depending on the search engine. Some of the search 
terms that were used included “(ruminant OR cattle OR 
cow OR feedlot OR fed beef OR beef OR steer) AND 
(ionophore OR cattlyst OR laidlomycin OR aureomycin 
OR chlortetracycline OR tylosin OR tylan OR monen-
sin OR rumensin) AND (performance OR growth OR 
average daily gain OR adg OR daily gain OR weight 
gain OR hot carcass weight OR hcw OR carcass weight 
OR mortality OR deaths OR liver abscess OR hepatic 
abscess OR feed gain OR dry matter intake OR dmi) 
AND (trial OR clinical trial OR rct OR randomiza-
tion OR rcbd).” Electronic databases accessed through 
the Kansas State University library included Medline/
Pubmed (http://www.ncbi.nlm.nih.gov/pubmed; ac-
cessed March 1, 2015), Agricola (http://agricola.nal.usda.
gov/; accessed March 1, 2015), CAB Direct (http://www.
cabdirect.org/; accessed March 1, 2015), Scopus (in-
cludes Medline and Embase; http://www.scopus.com/; 
accessed March 1, 2015), Google Scholar (https://scholar.
google.com/; accessed March 1, 2015), and USDA-ARS 
Current Research Information System (CRiS; http://
cris.nifa.usda.gov/cgi-bin/starfinder/0?path=crisassist.
txt&id=anon&pass=&OK=OK; accessed March 1, 
2015) and TekTran (http://www.ars.usda.gov/services/
tektran.htm; accessed March 1, 2015). In addition, arti-
cles retrieved from a hand search of published documents 
as well as industry reports were reviewed for inclusion. 
Reference lists from review articles were reviewed to 
identify relevant articles not captured during the search 
of electronic databases. Final reports and data from RCT 
comparing LP to MS at commercial approved doses, 
which were initiated by industry researchers and pharma-
ceutical companies and performed in feedlots in multiple 
states, were identified and reviewed for relevance.
Relevance Screening
The title and abstract of articles identified through 
electronic databases and a hand search, as well as un-
published industry reports, were screened for relevance 
based on preset inclusion and exclusion criteria (Table 
1). Articles deemed relevant to direct comparisons of 
interventions are depicted in Table 2. Two reviewers 
independently assessed the relevance of the articles and 
reports. When conflicts arose, those were resolved by 
consensus. Only results from studies reporting direct 
comparisons between LP and MS at commercially ap-
proved dosages (LP [Cattlyst] at approximately 11 g/t 
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DM with or without chlortetracycline [Aureomycin = 
350 mg/animal per day; Zoetis LLC; the level indicated 
for control of bacterial pneumonia] and MS [Rumensin] 
at 27–33 g/t DM with or without tylosin [Tylan = 9 g/t 
DM; Elanco Animal Health]) in the United States and 
produced from their corresponding manufacturers were 
included in the analysis. If citations did not pass the 
screening, those studies were not further considered. 
Originally, the search strategy for year of publication 
was set to start at 1994, the year when LP was released 
to the market; however, that criterion was relaxed to 
allow retrieval of studies from any publication year. 
Although not yet approved by the U.S. Food and Drug 
Administration at the time, 3 industry reports from 1989 
(Freeman et al.; Hale; and Lofgreen, unpublished data) 
and 1 peer-reviewed article from 1992 (Galyean et al., 
1992) were obtained and retained for further analysis as 
they comprised direct comparisons between LP and MS 
at commercial dosages (Table 3; Freeman et al., 1991; 
Galyean et al., 1992). Full-text articles or full reports 
from studies that passed the relevance screening were 
obtained and their risk of bias was assessed and then 
they were advanced to the data extraction step.
Risk of Bias Assessment
After full-text article retrieval, 2 reviewers indepen-
dently evaluated the risk of bias using a set of quality 
criteria designed to assess internal and external valid-
ity factors. Disagreements were resolved by consensus. 
Quality criteria evaluated issues related to confounding, 
selection, and information bias as well as external va-
lidity issues. Internal validity (or bias) factors assessed 
included study design (RCT), study implementation 
(randomization and blinding), and study analysis (clus-
tering and outcome assessment). External validity (or 
generalizability) factors appraised included animal pro-
duction setting (commercial or research feedlot) and 
study population (finishing steers). Risk of bias was as-
sessed for each design feature in each study as present, 
absent, or not reported. This evaluation was conducted 
to determine the potential influence of bias on results 
but not as an exclusion criterion. Hence, no articles were 
removed based on the risk of bias assessment. A fur-
ther assessment of the risk of bias consisted of stratified 
meta-analyses and meta-regression analyses conducted 
to explore pen size and type of production setting as 
potential sources of between-study heterogeneity.
Data Extraction
A data extraction spreadsheet was developed, 
where each column represented a field of interest for 
extracting data from the industry reports and full pa-
pers. Data extraction was independently performed by 2 
reviewers and disagreements were resolved by consen-
sus. Data extracted included the following: author; title; 
year of study; month of study; study location (country, 
state, and city); sex; days on feed; pen size; number of 
pens per treatment; number of animals per treatment; 
table 1. Exclusion and inclusion criteria for eligibility of studies assessing the effects of laidlomycin propionate 
versus monensin sodium on different performance, health, and carcass outcomes in finishing steers
Item Inclusion criteria Exclusion criteria
Cattle type Beef cattle Dairy, cow–calf, other
Sex/category Steer Heifer, mixed
Breed Continental, British, or crossbreed Holstein
Age Finishing cattle Calves, background cattle, pasture
Days on feed 80–240 d <80 or >240 d
Interventions and 
dosage
Direct comparisons between laidlomycin propionate (approximately 11 g/t DM) 
and monensin sodium (approximately 27 to 33 g/t DM) with or without antimi-
crobial combinations (chlortetracycline [350 mg/animal per day] and tylosin [9 
g/t DM], respectively)
Indirect comparisons and doses other than those 
commercially approved
Administration route In feed Any other than in feed delivery
Performance outcomes Mean and SE (SD, variance, or P-value) of ADG, DMI, and feed efficiency No measures of variability provided
Carcass outcomes Mean and SE (SD, variance, or P-value) of HCW, number or proportion of total 
livers with abscesses, total livers with no abscesses, A abscesses, and A+ ab-
scesses
No measures of variability provided for HCW
Health outcomes Number or proportion of respiratory deaths or mortality, digestive m.ortality, 
overall mortality, total mortality, and removals
Study design Randomized controlled trials Laboratory (in vitro) and observational
Region/country North America (the United States, Canada, and Mexico) Other than the United States, Canada, and Mexico
Language English Other than English
Publication year 1994–20151 See below1
1Initially, the search was restricted to studies published after 1994; however, we expanded the search to also include articles published before 1994.
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breed; treatment; treatment dose; use of antimicrobi-
als and dosage; use of implants; day of implant; other 
preventative measures (coccidiostatics, vaccines, and 
β-agonists); mean, SEM, or SD of ADG; initial weight; 
final weight; DMI; FE; HCW; number of morbid ani-
mals and deaths (digestive, respiratory, and any cause); 
and liver abscess (number, percent, total, A+, A, and 
no abscesses; Table 4). The FE outcome variable used 
consisted of the ratio of feed weight to BW gain, rather 
than the inverse (G:F), because several older study re-
ports did not include the latter (or data for calculations). 
Data for each treatment group (LP and MS) pertaining 
to the number of pens per treatment, number of animals 
per treatment, mean outcomes, and their measures of 
variability were extracted from relevant studies. If an 
article reported results for different trials, given a dif-
ferent dietary combination or management program, or 
performed in a different group of animals, those results 
were treated as separate data sets within a study. If data 
from a study were reported in both an industry report 
and a peer-reviewed publication, the latter was used. 
The specific studies from which data were extracted 
from and that contributed estimates for different out-
come-specific meta-analyses are included in Table 3.
Outcome and Summary Measures
Outcome measures pertaining to performance 
characteristics (ADG, DMI, FE, and HCW) were 
computed on a live weight and/or carcass-adjusted ba-
sis, after excluding the cattle that died or did not finish. 
Health outcomes were extracted as proportions or per-
centages, or percentage of the events of interest were 
calculated from the studies by considering the number 
of events of interest reported in each treatment group 
as the numerator and the number of animals in each 
treatment group as the denominator. Definitions and 
units for all outcome measures are depicted in Table 3.
For performance outcomes measured on a continu-
ous scale (Table 4), the mean of each treatment group 
was recorded, along with the SEM, SD, variance, or 
P-value. In all cases, those means accounted for the 
hierarchical structure of the study design (animals 
clustered within pens). Means and measures of vari-
ability for the outcomes of interest were entered into 
an electronic spreadsheet. Mean and SEM reported 
using the English system (lb) were transformed to the 
International System of Units system (kg) by multiply-
ing those values by 0.453592. When an overall SEM 
was reported for each treatment group, a pooled SD 
was derived from the formula SDp = SEMp × (np)
1/2, in 
which SDp is the pooled SD, SEMp is the overall SEM 
provided by the study, and np is the number of indi-
viduals in both treatment groups (Lean et al., 2009). For 
studies reporting only P-values, an estimate of a com-
mon SD was computed using the mean treatment differ-
ence (x2 – x1), the t-statistic (tαdfE which corresponds to 
the percentile from the reference distribution [tinv is the 
two-tailed inverse of the Student’s t-distribution which 
can be calculated using  (P-value, df); df = (n LP + n 
MS) – 2)]), and the sample size of each treatment group 
(n) using the following formula reported in Mederos et 
al. (2012): Sp = (x2 – x1)/{tαdfE[(1/n2) + (1/n1)]
1/2}.
For dichotomous measures (Table 4; mortality and 
liver abscesses), outcomes were converted to the loga-
rithm of the odds ratios (or) using the following for-
mula: lnOR = ln(ad/bc). The SE of the log OR were cal-
culated as follows: SE(lnOR) = [(1/a) + (1/b) + (1/c) + 
(1/d)]1/2, in which a is the number of events in group 
1 (LP), b is the number of events of interest in group 2 
(MS), c is the number of subjects with no events in group 
1, and d corresponds to the number of subjects with no 
events in group 2 (Bradburn et al., 1998). Data entries 
table 2. Number of articles retrieved from electronic 
databases, hand search, and industry reports and num-
ber of relevant articles identified for direct compari-
sons of interventions
 
 
Source1
Original 
search2
Relevance 
screening3
Relevant 
articles4
No. of studies
Electronic databases (J)
Scopus 1,447 67 35
Pubmed 212 17 0
Agricola 158 27 0
Google Scholar 360 12 0
TekTran 52 0 0
USDA Current Research 
Information System (CRIS)
59 0 0
CAB Direct 4 1 0
Hand search (CP) 4 4 2
Industry reports (IR) 34 17 96
Total 2,330 145 147
1J = peer-reviewed journal publications; CP = conference proceedings 
(reports available online); IR = industry reports. Agricola (http://agricola.
nal.usda.gov/; accessed March 1, 2015), CAB Direct (http://www.cabdirect.
org/; accessed March 1, 2015), Google Scholar (https://scholar.google.com/; 
accessed March 1, 2015), Medline/Pubmed (http://www.ncbi.nlm.nih.gov/
pubmed; accessed March 1, 2015), Scopus (includes Medline and Embase; 
http://www.scopus.com/; accessed March 1, 2015), TekTran (http://www.
ars.usda.gov/services/tektran.htm; accessed March 1, 2015), and USDA-
ARS Current Research Information System (CRiS; http://cris.nifa.usda.
gov/cgi-bin/starfinder/0?path=crisassist.txt&id=anon&pass=&OK=OK; ac-
cessed March 1, 2015). 
2Includes duplicates (articles retrieved in more than 1 database).
3Relevance screening based on screening of title and abstract and after 
removal of duplicates, non-English articles, and studies from regions other 
than North America, among other criteria.
4Only direct comparison of treatments.
5Three articles comprising 4 data sets.
6Nine industry reports comprising 11 data sets.
7Total of 14 studies comprising 17 data sets in total.
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equivalent to 0 in any of the cells (a, b, c, and d) were 
replaced with a value of 0.005 to enable transformation.
Data Analysis
Extracted data were incorporated into meta-anal-
yses models to compute summary estimates for the 
different outcomes of interest. The following models 
were concurrently fitted: 1) a fixed-effect meta-analysis, 
where each study was weighted using an inverse vari-
ance method, and 2) a random-effects meta-analysis 
DerSimonian and Laird (1986) model to account for the 
heterogeneity between studies. Mean differences (Md) 
and standardized mean differences (SMd) for continu-
ous outcomes and OR for dichotomous outcomes and 
their 95% confidence intervals were obtained in meta-
analysis models using the “metan” command in Stata 
12.0 (StatCorp LP, College Station, TX).
Given that some of the continuous outcomes (e.g., 
ADG, DMI, FE) may not have been measured following 
the exact same procedure (a few articles did not report 
how some of the outcomes were measured or calculat-
ed) but likely were a reasonable proxy for the outcomes 
of interest, SMD also were used as summary statistics 
(O’Connor et al., 2014b). Therefore, summary effects 
for all continuous outcomes were expressed as both MD 
and SMD. Mean difference or difference in means esti-
mates the amount by which LP changes the outcome on 
average compared with MS (Higgins and Green, 2011). 
Standardized mean differences reflect the treatment ef-
fect relative to the variability observed in the outcome 
in each study (Dohoo et al., 2009) and correspond to the 
number of SD difference. A guideline for interpreting 
SMD proposed by Cohen (1988) is as follows: 0.2 rep-
resents a small effect, 0.5 represents a moderate effect, 
and 0.8 represents a large effect (Cohen, 1988; Higgins 
and Green, 2011). For analyses of liver abscesses out-
comes, only those studies explicitly reporting the use of 
ionophores concurrently fed with antimicrobials (chlor-
tetracycline and tylosin) were included in meta-analysis 
models, as these specific antimicrobial drugs are fed in 
combination with the interventions of interest for the 
purpose of disease prevention.
Between-study heterogeneity was quantified using 
Cochrane’s χ2 test of homogeneity (Q) and the I2 statis-
tic (Higgins et al., 2003; Higgins and Thompson, 2004). 
Cochrane’s Q statistic was used to evaluate whether 
the variation between studies exceeds that expected 
by chance and is used to compute the I2 statistic: I2 = 
[(Q – df)/Q] × 100 (Higgins et al., 2003). A P-values 
less than 0.10 indicates significant between-study het-
erogeneity. The I2 statistic represents the percentage of 
variation across studies that is due to heterogeneity rath-
er than chance (I2 25–50% represents a low degree of 
table 3. Summary of relevant data sets that were included in meta-analysis models
First author/investigator,  
  study year1
 
Location
 
Source1
Production
setting
Number
of data sets
Pens/
treatment
Steers/
pen
Steers/
treatment
Bryant T., 2010 Oklahoma IR Commercial 1 15 135 2,025
Swingle S., 2010a2 Texas IR Commercial 1 6 81 to 132 589 to 614
Swingle S., 2010b3 Texas IR Commercial 1 6 81 to 132 573 to 593
Swingle S., 1998 Texas IR Commercial 1 10 80 to 107 942
Hunsaker B., 20084 Colorado IR Research 1 16 10 160
Hunsaker B., 20085 Colorado IR Research 1 6 100 600
Cooper R., 2010 Nebraska IR Commercial 1 6 73 438
Hunsaker B., 2010 Colorado IR Research 1 6 10 60
Johnson E., 2009–2010 Idaho IR Commercial 1 8 100 800
Freeman A., 1989 Kansas CP Research 1 4 10 40
Lofgreen G., 1989 New Mexico IR Research 1 4 15 60
Hale R., 1989 Colorado IR Research 1 5 8 39
Domby E., 2010–2011 Colorado J Research 1 24 9 216
Gibb D., 20086 Alberta, Canada J Research 1 4 15 60
Gibb D., 20087 Alberta, Canada J Research 1 4 15 60
Galyean M., 1992 New Mexico J Research 1 6 12 72
Kreikemeier K., 1995 Kansas CP Research 1 5 9 45
Total 17 135 6,779 to 6,824
1J =  peer-reviewed journal publications; CP = conference proceedings (reports available online); IR = industry reports; Freeman A., 1989 (Freeman et al., 1991); 
Domby E., 2010-2011 (Domby et al., 2013); Gibb D., 2008 (Gibb et al., 2008); Galyean M., 1992 (Galyean et al., 1992); Kreikemeier K., 1995 (Kreikemeier, 1997).
2No beta agonist.
3Zilpaterol hydrochloride.
4Progesterone and estradiol benzoate.
5Trenbolone acetate and estradiol.
6Steam-rolled corn.
7Ground corn.
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heterogeneity, I2 50–75% represents a moderate degree 
of heterogeneity, and I2 ≥ 75% represents high degree 
of heterogeneity; Higgins et al., 2003).
When the test of heterogeneity (Cochrane’s χ2) 
tended to be significant (P < 0.10) in meta-analysis 
models, pooled summary estimates from random-effect 
models were presented. When the heterogeneity test of 
meta-analysis models did not tend to be significant (P > 
0.10), indicating that between-study differences are 
explicable by random variation, summary estimates 
from fixed-effect models were depicted. When hetero-
geneity is low, fixed- and random-effect models tend 
to produce very similar estimates. Size of study pen 
(<50 steers/pen and >50 steers/pen) was considered an 
a priori confounder and potential cause of heterogene-
ity between studies. Hence, when substantial hetero-
geneity was identified (I2 > 50%), a stratified analysis 
(i.e., pooled estimates are obtained by each subgroup 
or strata) was conducted to explore size of study pens 
as a potential cause of heterogeneity. Moreover, me-
ta-regression models were fitted to investigate size of 
study pens (<50 steers/pen and >50 steers/pen) and 
type of production setting (commercial operation and 
research feedlot) as factors that could potentially ex-
plain the heterogeneity between studies. Mixed-effects 
meta-regression models with residual maximum like-
lihood and the Knapp–Hartung variance modification 
were fitted using the “metareg” command in Stata.
ReSulTS
Systematic Review of the Literature
A total of 2,292 articles were obtained from 
Medline/Pubmed, Agricola, CAB Direct, Scopus (in-
cludes Medline and Embase), Google Scholar, and 
USDA-ARS CRIS and TekTran and 2 were obtained 
from a hand search. After duplicate removal and rel-
evance screening (i.e., screening of title and abstracts 
and removal of non-English articles and studies from 
regions other than North America), only 128 articles 
were deemed relevant. A further screening aiming to 
explore direct comparisons between treatments re-
trieved 5 articles: 3 obtained from Scopus comprising 
4 data sets and 2 from a hand search. From a total of 
34 industry reports (produced by different companies 
acquiring the products: Syntex, 1994; Roche, 1995; 
Alpharma, 2000; Pfizer, 2010; Zoetis, 2013) conduct-
ed from 1989 to 2010, 17 reports were deemed rele-
vant, and 9 reports, comprising 11 data sets, described 
direct comparisons. Two industry reports were pub-
lished in a peer-reviewed publication and a conference 
table 4. List of performance, health and carcass outcome measures, definitions, units, and type of outcomes for 
statistical analyses
Outcome measure
  (acronym)
 
Description
 
Units
Type  
of outcome1
ADG
Live weight, deaths excluded Mean number of kilograms gained daily based on total weight gained over total days 
on feed; measurements based on live or carcass-adjusted weight; deaths not included
kg/d MD and SMD
Carcass adjusted, deaths excluded kg/d MD and SMD
DMI
Deaths excluded Amount of feed cattle consume per day on a moisture-free basis; deaths not included kg/d MD and SMD
Feed efficiency
Live weight; deaths excluded Feed conversion ratio: kilograms DMI to kilograms of weight gain; measurements 
based on live or carcass-adjusted weight; deaths and removed cattle not included
NA2 MD and SMD
Carcass adjusted; deaths excluded NA MD and SMD
HCW Hot or unchilled weight of the carcass after slaughter and removal of head, hide, 
intestinal tract, and internal organs
kg MD and SMD
Respiratory mortality Proportion of deaths attributed to BRD during the study period for each treatment 
group
% OR
Digestive mortality Proportion of deaths attributed to digestive disturbances during the study period for 
each treatment group
% OR
Overall mortality Proportion of deaths (due to any cause) among the study population (for each treat-
ment group)
% OR
Total mortality and removals Proportion of total deaths and removals (due to any cause) among the study popula-
tion (for each treatment group)
% OR
Total livers with abscesses Total proportion of cattle with liver abscesses observed during harvest3 % OR
Proportion of A livers Proportion of cattle with 2 to 4 well-organized abscesses3 % OR
Proportion of A+ livers Proportion of cattle with 1 or more large or multiple small, active abscesses3 % OR
Total livers with no abscesses Proportion of livers with no abscesses (scored 0)3 % OR
1MD = mean difference; SMD = standardized mean difference; OR = odds ratio.
2NA = not applicable.
3Nagaraja and Chengappa, 1998.
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proceeding; therefore, the latter forms were used for 
data extraction purposes (Table 2).
Relevance Screening
An extensive number of studies obtained from 
electronic databases did not meet the inclusion or ex-
clusion criteria (Table 2). Only data from RCT, with 
random assignment of cattle pens to treatments, were 
used in this study to assure an objective assessment of 
effects. Studies where the treatments were administered 
through a route other than in feed were excluded; stud-
ies where cattle were administered a ruminal fistula 
were excluded, as our goal was to include only animals 
administered the products under commercial-type con-
ditions. In all studies, treatments were administered at 
the pen level (in feed). Only studies appropriately ac-
counting for multiple organizational levels or cluster-
ing (animals nested within pens) in their analyses were 
included. Hence, multilevel models had to be applied 
to analyze these types of data. Studies published in lan-
guages other than English were excluded due to budget-
ary constraints for using translational services.
Risk of Bias Assessment
Full-text articles and reports were subjected to a 
risk of bias assessment evaluating a set of criteria per-
taining to internal and external validity factors. All peer-
reviewed studies and industry reports that passed the 
relevance screening and met the eligibility criteria were 
RCT with a random assignment of animals into pens 
and treatments randomly assigned to pens. Blinding, 
however, was reported in only 1 study. Eleven of the 
total 14 relevant studies explicitly reported how the 
outcomes were measured (e.g., live, carcass adjusted, 
deaths in or out). The lack of independence of outcome 
measures due to the existence of a hierarchical orga-
nizational structure (e.g., animals within pens) and/or 
repeated measures was accounted for in the statistical 
analysis of all relevant studies. Five studies were con-
ducted in commercial feedlots and 9 were conducted in 
research feedlots. The study population in all relevant 
studies comprised finishing steers.
Except for blinding, internal validity issues pertain-
ing to study design and implementation were deemed 
of low risk. The study population of interest was con-
sidered a potential confounder, and its confounding 
effect was controlled for by using a restricted popula-
tion (i.e., finishing steers) during relevance screening. 
External validity questions pertaining to population and 
outcomes assessment were deemed of low to unclear 
risk, as all studies were conducted in finishing steers 
and only a few studies did not explicitly define how the 
outcomes were measured. Another potential confound-
er considered a priori was the size of the study pens, and 
hence, a stratified analysis was conducted to determine 
its effect on the different outcomes of interest for both 
intervention groups (see below).
Data Extraction and Meta-Analyses
Data were extracted from a total of 14 articles com-
prising a total of 17 data sets: 6 data sets were extracted 
from 5 peer-reviewed publications and hand search re-
ports and 11 data sets were derived from 9 industry re-
ports (Table 3). Data were pooled from RCT conducted 
in various geographic areas of the United States and 
Alberta, Canada, comprising a total of 13,605 finishing 
steers. The Continental, British, or crossbreed steers were 
on feed, on average, from 112 to 187 d. Interventions LP 
and MS were fed at dietary concentrations that ranged 
between 11 and 11.1 g/t and 27.8 and 33.3 g/t of feed, 
DM basis, respectively. Steers’ initial weight ranged 
from 283 to 387 kg, with a mean of 340 kg (SD 28). After 
excluding deaths and animals removed from the study, 
carcass-adjusted final weight ranged from 561 to 658 kg, 
with a mean of 622 kg and SD of 31 kg.
Results from meta-analyses are presented in Tables 
5 and 6, which include continuous and categorical out-
comes, respectively. Figures 1 to 5 include forest plots 
used to demonstrate effects on performance and health 
outcomes. When using forest plots to present results, 
each horizontal line represents the results from 1 study 
or data set, depicted by the name of the first author and 
the publication or study year (see Table 3 for more 
information). The length of the horizontal line repre-
sents the 95% confidence interval for the parameter 
estimate (e.g., MD), the center of the shaded box rep-
resents the point estimate of the parameter, and the 
area is proportional to the assigned weight. The empty 
diamond at the bottom shows the confidence interval 
and the dotted vertical line represents the overall ef-
fect parameter based on random-effects (DerSimonian 
and Laird [1986] model; preferred estimation) models.
Effects on Performance Parameters
Meta-analyses results indicated that steers fed LP 
had a greater ADG, based on live and carcass-adjusted 
measurements, compared with steers fed MS (Table 5; 
Fig. 1). Likewise, feeding LP increased DMI in finish-
ing steers compared with feeding MS (Table 5; Fig. 2). 
However, MD in FE based on live weight and carcass-
adjusted measurements were not significantly different 
for LP compared with MS (Table 5; Fig. 3). Although 
all performance outcomes were measured in the same 
unit, it was not clear whether all studies used the exact 
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same measurement or calculation procedures. Although 
there are no consensus guidelines about reporting results 
in these situations (Takeshima et al., 2014), we decided 
to report both MD and SMD. Consistent with MD results 
for ADG (live and carcass adjusted) and DMI, the result-
ing significant SMD > 0.50 indicate a moderate increase 
associated with LP in comparison with MS (Table 5).
Effects on Health-Related Parameters
Results from the meta-analysis models for health-
related parameters (i.e., respiratory mortality, diges-
tive mortality, overall mortality, and total mortality 
and removals) demonstrated no statistically significant 
differences (P > 0.05) between LP- and MS-fed cattle 
(Fig. 4). Measures of associations from meta-analyses 
are presented for reference in Table 6.
Effects on Carcass Parameters
The meta-analysis for HCW indicated that steers 
fed LP were associated with a HCW increase compared 
with steers fed MS (Table 5; Fig. 5). Only studies where 
it was explicitly reported that antimicrobials (chlortet-
racycline or tylosin) were concurrently administered 
with the main interventions (LP and MS) were included 
for analysis of liver abscess–related outcomes. Steers 
fed LP had significantly greater odds of having liver ab-
scesses (OR = 1.40, P = 0.01) and A+ livers (OR = 1.60, 
P < 0.01) than steers fed MS (Table 6). Laidlomycin 
propionate–fed steers tended to be significantly more 
table 5. Results obtained from random-effects meta-analysis models of the effects of laidlomycin propionate 
compared withmonensin sodium on performance outcomes
 
 
Outcome,1 units
 
Number
of data sets
 
 
MD2
95% CI3  
MD = 0
P-value4
 
 
I2,5 %
 
 
SMD6
95% CI  
SMD = 0
P-value4
 
 
I2,5 %
Lower, upper
MD
Lower, upper
SMD
ADG (live), kg/d 16 0.05 0.04, 0.07 <0.01 92.2 0.61 0.40, 0.81 <0.01 96.4
ADG (carcass adjusted), kg/d 8 0.06 0.04, 0.08 <0.01 95.6 0.67 0.43, 0.90 <0.01 97.2
DMI, kg/d 17 0.29 0.23, 0.36 <0.01 93.4 0.68 0.53, 0.83 <0.01 93.0
FE (live) 16 0.02 –0.07, 0.11 0.65 99.9 0.20 –0.17, 0.56 0.28 98.7
FE (carcass adjusted) 9 –0.03 –0.08, 0.03 0.31 96.5 –0.16 –0.41, 0.10 0.23 97.8
HCW, kg 17 5.36 3.86, 6.87 <0.01 94.5 0.57 0.39, 0.74 <0.01 95.3
1For explanation of outcome measures, see Table 4. FE = feed efficiency.
2MD = mean difference.
3CI = confidence interval.
4Test (Z-test) of the null hypothesis of no difference in means (MD = 0) or standardized mean differences (SMD) between interventions (SMD = 0).
5I2 = variation in MD or SMD attributable to heterogeneity (I2 25–50% represents a low degree of heterogeneity, I2 50–75% represents a moderate degree of 
heterogeneity, and I2 ≥ 75% represents high degree of heterogeneity; Higgins et al., 2003); P-values for Cochran’s Q test (χ2 test; df = k – 1, in which k = num-
ber of studies) to assess the statistical significance of between-study heterogeneity were <0.001 for all outcomes (P-values < 0.10 are considered significant).
6SMD = standardized mean difference.
table 6. Results obtained from random-effects meta-analysis models of the effects of laidlomycin propionate 
compared with monensin sodium on health-related outcomes and liver abscesses
 
Outcome
Number
of data sets
 
OR1
95% CI2 OR = 1
P-value3
Cochran’s Q
P-value4
 
I2,5 %Lower, upper OR
Respiratory mortality 9 1.34 0.36, 4.99 0.67 0.99 0.0
Digestive mortality 8 1.77 0.92, 3.41 0.09 0.72 0.0
Overall mortality 9 1.27 0.82, 1.96 0.28 0.79 0.0
Total mortality and removals 10 1.01 0.76, 1.34 0.96 0.80 0.0
Proportion of A livers 8 1.29 0.95, 1.75 0.10 <0.01 75.4
Proportion of A+ livers 10 1.60 1.29, 1.99 <0.01 0.32 13.3
Total livers with abscesses 12 1.40 1.07, 1.83 0.01 <0.01 80.3
Total livers with no abscesses 9 0.78 0.61, 1.02 0.07 <0.01 82.5
1OR = odds ratio.
2CI = confidence interval.
3Test of OR = 1.
4P-value for Cochran’s Q test (χ2 test; df = k – 1, in which k = number of studies) to assess the statistical significance of between-study heterogeneity. 
P-values < 0.10 are considered significant.
5I2 = variation in OR attributable to heterogeneity (I2 25–50% represents a low degree of heterogeneity, I2 50–75% represents a moderate degree of 
heterogeneity, and I2 ≥ 75% represents high degree of heterogeneity; Higgins et al., 2003).
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likely to have A livers (OR = 1.29, P = 0.10) but less 
likely to have no liver abscesses compared with MS-fed 
steers (OR = 0.78, P = 0.07; Table 6).
Stratified Meta-Analyses and Meta-Regression Models
Performance (ADG, DMI, and FE) and carcass 
(HCW, total livers with abscesses, and A and A+ livers) 
outcomes had a substantial variability (I2 > 50%) in the 
effects of LP compared with MS between studies. A pri-
ori, it was considered that the size of study pens was a 
potential confounder and cause of heterogeneity among 
relevant studies. When stratified meta-analyses were 
conducted by size of study pens, this variable seemed 
to account for some of the heterogeneity among stud-
ies for ADG (live weight), FE (carcass adjusted), and 
HCW, as indicated by numerical differences in MD and 
SMD for LP compared with MS in different size pens 
(data not shown). Overall, when stratified by size of the 
study pens, overall tests of between-group heterogene-
ity could not be interpreted, given considerable hetero-
geneity in 1 subgroup (pens with >50 steers/pen).
To explain potential causes of between-study hetero-
geneity, mixed-effects meta-regression models were fitted. 
Six to 17 studies were used to fit meta-regression models 
depending on outcome and explanatory variables. Given 
the limited number of relevant studies, only univariable 
models were built. The type of production setting tended 
to be significant (P = 0.09) and it explained 29% of the be-
tween-study variance for ADG based on live weight. Pen 
size was significant (P = 0.04) and it explained 59% of the 
between-study variance for FE (carcass adjusted). Except 
for these associations, there was no evidence of these ex-
planatory variables significantly (P > 0.10) explaining the 
heterogeneity between studies for the other outcomes of 
interest when comparing steers fed LP and MS.
Figure 1. Forest plot obtained from random-effects meta-analysis models of the effects of laidlomycin propionate versus monensin sodium on ADG (live 
weight). Each horizontal line represents the results from a data set, depicted by the name of the primary investigator and the publication or study year (see Table 3). 
The length of the horizontal line represents the 95% confidence interval (CI) for the parameter estimate (mean difference), the center of the shaded box represents 
the point estimate of the parameter, and the area is proportional to the assigned weight. The empty diamond at the bottom shows the confidence interval and the 
dotted vertical line represents the overall effect parameter based on the random effects (DerSimonian and Laird, 1986) model. Weighted mean difference (WMD) 
computes a weighted average of differences in means; however, no weighting occurs when calculating a statistical summary of a single study; therefore, we refer to 
the results of meta-analysis as mean differences (Higgins and Green, 2011). I-squared =  I2 or variation in MD  attributable to heterogeneity (I2 0-50% = low hetero-
geneity; 50-75% = moderate; >75% = high heterogeneity (Higgins et al., 2003); p = P-value for Cochran’s Q test Freeman A., 1989 (Freeman et al., 1991); Domby 
E., 2010-2011 (Domby et al., 2013); Gibb D., 2008 (Gibb et al., 2008); Galyean M., 1992 (Galyean et al., 1992); Kreikemeier K., 1995 (Kreikemeier, 1997).
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diSCuSSioN
The meta-analysis of data from these compara-
tive effectiveness studies demonstrate significant MD 
between steers fed LP and steers fed MS with respect 
to several important feedlot performance and carcass 
outcomes. Laidlomycin propionate is an ionophore ap-
proved for use in combination with chlortetracycline 
for improved FE and increased rate of weight gain in 
cattle fed in confinement for slaughter (FDA, 2015a). 
Monensin sodium, also an ionophore, is approved for 
use in combination with tylosin for increased FE in 
feedlot cattle and with an additional claim for the pre-
vention and control of coccidiosis (FDA, 2015b). The 
results of the present study indicate beneficial effects 
of feeding LP as compared with MS for most feedlot 
performance (e.g., live and carcass-adjusted ADG) 
and carcass parameters (e.g., HCW) but not for others 
(Tables 5 and 6). Although digestive mortality tended to 
favor MS, none of the mortality-related outcome vari-
ables differed significantly (Table 6). Liver abscesses 
were significantly more common in LP-fed cattle than 
in MS-fed cattle (Table 6), presumably because of dif-
ferences in the concurrently fed antimicrobials. Some 
MD may not have been identified in single field studies, 
as the magnitude of effects was relatively small com-
pared with the sample sizes for individual studies and 
meta-analysis of results from several individual studies 
can increase the power for detecting effects (Dohoo et 
al., 2009). However, there was evidence for significant 
heterogeneity among studies, which could not be fully 
explained with the few potential explanatory variables 
and the relatively small number of data sets available 
for analyses. The significant heterogeneity among stud-
ies could be expected given the diversity of studies 
included. However, these results provide unique and 
comprehensive information on the comparative effects 
of different ionophores across multiple studies and in 
multiple years, states, and production settings.
A systematic review of multiple RCT is consid-
ered the strongest evidence for intervention efficacy 
in human and animal health research (Sargeant et al., 
2014b). The results presented here are based on RCT 
that directly compared interventions (LP and MS) in a 
Figure 2. Forest plots obtained from random-effects meta-analysis models of the effects of laidlomycin propionate versus monensin sodium on DMI. 
WMD = weighted mean difference; CI =  confidence interval; I-squared =  I2 or variation in MD  attributable to heterogeneity (I2 0-50% = low heterogene-
ity; 50-75% = moderate; >75% = high heterogeneity (Higgins et al., 2003); p = P-value for Cochran’s Q test.
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comparative effectiveness format but did not include 
efficacy studies where interventions were compared 
with a negative control (for indirect comparisons of in-
terventions). By comparing with another intervention 
(i.e., a positive control), the results enable interpretation 
of whether an intervention is “as good as” or “better 
than” another intervention or interventions (Sargeant et 
al., 2014a). Analytical approaches incorporating both 
direct and indirect comparisons of interventions exist 
and are particularly useful when treatments have not 
been directly compared in randomized trials (Jansen et 
al., 2011). Indirect comparisons, besides being statisti-
cally less precise than direct comparisons and more un-
predictable, are also prone to many of the same biases 
as direct comparisons (Song et al., 2008). Bucher et al. 
(1997) and Glenny et al. (2005) have recommended 
that results from RCT on direct comparisons are used 
rather than conflicting evidence from indirect com-
parisons. The focus here toward including only direct 
comparisons aimed to increase the usefulness as well as 
practicability and understanding of results for the end 
users (O’Connor et al., 2014b).
Most studies of direct comparisons between LP 
and MS were not publicly available. Given the rela-
tively common use of these interventions and the 
similarities in approved label indications, there was a 
general lack of evidence as it relates to direct compari-
sons between LP and MS. The limited number of direct 
comparisons raises the possibility for publication bias 
if studies with unfavorable results have not been pub-
lished. Publication bias is a concern in any review that 
combines data from multiple sources. Because smaller 
studies (with larger SE) are less likely to find positive 
results, they may be more prone to not being published 
(O’Connor et al., 2014b). To avoid this potential bias, 
data not available to the public domain (e.g., industry 
reports) as well as unindexed reports (e.g., conference 
proceedings) were also included in this meta-analysis. 
In addition to articles indexed in electronic databases, 
a hand search of references in review papers as well as 
communication with scientists, manufacturing compa-
nies, and industry partners, who have been working in 
the relevant field, are all considered important methods 
for a comprehensive search (Lean et al., 2009). It may 
Figure 3. Forest plots obtained from random-effects meta-analysis models of the effects of laidlomycin propionate versus monensin sodium on feed 
efficiency (live weight; the ratio of feed weight to BW gain). WMD = weighted mean difference; CI =  confidence interval; I-squared =  I2 or variation in 
MD  attributable to heterogeneity (I2 0-50% = low heterogeneity; 50-75% = moderate; >75% = high heterogeneity (Higgins et al., 2003); p = P-value for 
Cochran’s Q test.
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not be possible to find every relevant study on a topic, 
but pursuing multiple avenues to find as many relevant 
studies as possible can minimize publication bias and 
increase the precision of the pooled estimates of effect 
while providing meaningful results of most importance 
to decision makers (Lean et al., 2009).
Sources of bias also can arise from lack of ran-
domization or inadequate blinding. In the current 
study, randomization was implemented in all studies. 
Blinding was reported in only 1 of the studies; howev-
er, most outcome variables were objectively measured, 
and it is possible that blinding, a relatively common re-
porting flaw, was done but was not reported (Sargeant 
et al., 2014b). Given the scarcity of studies, we did not 
exclude any reports or publications based on the lack 
of reporting of blinding to treatment groups, other re-
porting omissions, or potential design flaws. However, 
studies had to be RCT and certain validity criteria had 
to be met (i.e., risk of assessment bias); only direct 
evidence from low-risk-of-bias studies was used.
Random-effects meta-analysis summary estimates 
were provided as they incorporate within-study and 
between-study variation. The summary effect mea-
sures were calculated as a weighted average of the ef-
fect sizes estimated in the individual studies based on 
the assumption that larger studies are likely more ac-
curate and, therefore, given larger weights (O’Connor 
et al., 2014b). A random-effects meta-analysis assumes 
that the effects being estimated in the different studies 
are not identical but likely follow a normal distribution. 
Random-effect estimates and their confidence intervals 
determine the average intervention effect. Furthermore, 
these models assume that a distribution of true treat-
ment effects exists across studies and that included 
studies are a random sample of the entire population of 
studies, and hence, inferences can be generalized be-
yond the studies included (Dohoo et al., 2009).
The summary estimates from these models should 
be interpreted with caution given the substantial be-
tween-study heterogeneity identified. When pen size 
and type of production setting were analyzed as potential 
causes of heterogeneity, they only partially explained 
the between-study variability for a few of the modeled 
outcomes. Unfortunately, data on other potentially ex-
planatory variables (e.g., diet) were not consistently re-
ported for the included studies and, consequently, could 
Figure 4. Forest plots obtained from fixed and random-effects meta-analysis models of the effects of laidlomycin propionate versus monensin sodium on 
digestive mortality. Each horizontal line represents the results from a data set, depicted by the name of the primary investigator and the publication or study year (see 
Table 4). The length of the horizontal line represents the 95% confidence interval (CI) for the parameter estimate (odds ratio), the center of the shaded box represents 
the point estimate of the parameter, and the area is proportional to the assigned weight. The empty diamonds at the bottom show the confidence intervals and the 
vertical dotted line represents the overall effect parameters based on fixed effects (I-V; Inverse variance) and random effects (DerSimonian and Laird, 1986) [D+L]) 
models. I-squared =  I2 or variation in MD  attributable to heterogeneity (I2 0-50% = low heterogeneity; 50-75% = moderate; >75% = high heterogeneity (Higgins 
et al., 2003); p = P-value for Cochran’s Q test.
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not be assessed. Caution should also be exercised when 
interpreting the results of the stratified meta-analyses 
and meta-regression models, as the number of studies 
included in each group was small. Higgins and Green 
(2011) proposed that a minimum of 10 studies are nec-
essary for conducting meta-regression analyses. As 
indicated by O’Connor et al. (2014b), there is no con-
sensus as to which pathway to take when unexplained 
heterogeneity is present. Therefore, we chose to report 
all relevant results and their potential limitations. The 
heterogeneity among studies was not unexpected given 
the diversity of studies with regard to year and site, and 
likely differences in cattle such as genetics, and man-
agement factors including advances in growth technol-
ogies and feed rations—a factor that is known to affect 
the performance responses of feedlot cattle fed iono-
phores (Vogel, 1995; Duffield et al., 2012).
The efficacy of ionophores for improving cattle per-
formance has been well documented in numerous stud-
ies (reviewed in Vogel, 1995; Birkelo, 2003). Recently, 
Duffield et al. (2012) conducted a meta-analysis of the 
effects of monensin (compared with negative controls) 
on performance parameters in beef cattle. However, this 
current report is the first systematic review and meta-
analysis to directly compare different ionophores (and 
their concurrently fed antimicrobials) and evaluate their 
comparative effectiveness on performance, carcass, and 
health-related outcomes in a feedlot setting. Across a di-
verse group of studies, there was an average increase in 
feed intake, weight gain, and HCW in steers fed LP com-
pared with those fed MS (Table 5); the linkages among 
these 3 outcomes are relatively intuitive. When address-
ing liver abscess data, studies not reporting the concur-
rent use of antimicrobials (chlortetracycline and tylosin) 
were not included in the meta-analyses, as these drugs are 
fed in combination with the interventions of interest for 
the purpose of disease prevention. The significant MD 
among treatments with regard to liver abscess data were 
not unexpected, given that tylosin has long been consid-
ered the most effective antimicrobial for preventing liver 
Figure 5. Forest plots obtained from fixed and random-effects meta-analysis models of the effects of laidlomycin propionate versus monensin sodium 
on digestive mortality. Each horizontal line represents the results from a data set, depicted by the name of the primary investigator and the publication or 
study year (see Table 3). The length of the horizontal line represents the 95% confidence interval (CI) for the parameter estimate (odds ratio), the center 
of the shaded box represents the point estimate of the parameter, and the area is proportional to the assigned weight. The empty diamonds at the bottom 
show the confidence intervals and the vertical dotted line represents the overall effect parameters based on fixed effects (I-V; Inverse variance) and random 
effects (DerSimonian and Laird, 1986) models.
Meta-analysis of laidlomycin and monensin 1675
abscesses (Nagaraja and Chengappa, 1998). In fact, it is 
important to explicitly state that the effects of ionophores 
and the effects of the concurrently fed antimicrobials can-
not be separated in this study. Most studies (71%, 12/17) 
used feeding programs consisting of an ionophore and an 
antimicrobial; hence, we could not disentangle specific 
effects that can be attributed to each product. However, 
this is a necessary and practical approach in studying 
their field effectiveness given the labeled usages of these 
products and their most common usages in the industry. 
It is also important to mention that all analyses and effect 
measures are for relative difference (i.e., relative differ-
ences between LP and MS), not measures of efficacy as 
compared with a negative control.
In conclusion, there were 17 data sets from over 20 
yr of research trials that could be used to assess the com-
parative effectiveness of feeding LP and MS in feedlot 
steers, but there was significant heterogeneity among 
studies that could not be fully explained in meta-regres-
sion models. Nevertheless, the data indicated signifi-
cant relative improvements in live and carcass perfor-
mance for LP-fed steers compared with MS-fed steers 
but negative relative effects on liver abscesses. These 
unique results can enable quantitative and informed de-
cisions by potential end users of these feed additives 
that are widely used in the U.S. beef industry for reduc-
ing the costs of beef production through increased cattle 
performance (Birkelo, 2003; USDA, 2011).
liTeRATuRe CiTed
Birkelo, C. P. 2003. Pharmaceuticals, direct-fed microbials, 
and enzymes for enhancing growth and feed efficiency of 
beef. Vet. Clin. North Am. Food Anim. Pract. 19:599–624. 
doi:10.1016/S0749-0720(03)00059-8.
Bradburn, M. J., J. J. Deeks, and D. G. Altman. 1998. Metan—A com-
mand for meta-analysis in Stata. Stata Tech. Bull. 44. Stata Press, 
StataCorp LP, College Station, TX. p. 4–15.
Bucher, H. C., G. H. Guyatt, L. E. Griffith, and S. D. Walter. 1997. 
The results of direct and indirect treatment comparisons in me-
ta-analysis of randomized controlled trials. J. Clin. Epidemiol. 
50:683–691. doi:10.1016/S0895-4356(97)00049-8.
Callaway, T. R., T. S. Edrington, J. L. Rychlik, K. J. Genovese, T. L. 
Poole, Y. S. Jung, K. M. Bischoff, R. C. Anderson, and D. J. Nisbet. 
2003. Ionophores: Their use as ruminant growth promotants and 
impact on food safety. Curr. Issues Intest. Microbiol. 4:43–51.
Cohen, J. 1988. Statistical power analysis in the behavioral sciences. 
2nd edition. Lawrence Erlbaum Associates, Inc., Hillsdale, NJ.
DerSimonian, R., and N. Laird. 1986. Meta-analysis in clinical 
trials. Control. Clin. Trials 7:177–188. doi:10.1016/0197-
2456(86)90046-2.
Dohoo, I., W. Martin, and H. Stryhn. 2009. Systematic reviews 
and meta-analysis. In: Veterinary epidemiologic research. 
2nd ed. VER Inc., Charlottetown, PEI, Canada. p. 739–771.
Domby, E. M., J. S. Schutz, J. J. Wagner, T. E. Engle, K. L. 
Neuhold, D. R. Woerner, and M. E. Branine. 2013. The ef-
fect of medicinal feed additive programs and dietary sulfur 
concentrations in steam-flaked corn diets containing wet dis-
tillers grains on performance and carcass merit in yearling 
feedlot steers. Prof. Anim. Sci. 29:566–574.
Donner, A., G. Piaggio, and J. Villar. 2001. Statistical methods 
for the meta-analysis of cluster randomization trials. Stat. 
Methods Med. Res. 10:325–338.
Duffield, T. F., J. K. Merrill, and R. N. Bagg. 2012. Meta-analysis 
of the effects of monensin in beef cattle on feed efficiency, 
body weight and dry matter intake. J. Anim. Sci. 90:4583–
4592. doi:10.2527/jas.2011-5018.
Freeman, A. S., H. R. Spires, and R. L. Botts. 1991. Performance of 
feedlot steers fed high energy diets containing laidlomycin propio-
nate with and without antibiotics. Cattle Feeders’ Day. Report of 
Progress 632. Kansas State University, Agricultural Experiment 
Station and Cooperative Extension Service. Southwest Research-
Extension Center. http://www.k-state.edu/historicpublications/
pubs/SRP632.pdf. (Accessed 27 August 2015.) p. 2–6.
Galyean, M. L., K. J. Malcolm, and G. C. Duff. 1992. Performance 
of feedlot steers fed diets containing laidlomycin propionate 
or monensin plus tylosin, and effects of laidlomycin propio-
nate concentration on intake patterns and ruminal fermenta-
tion in beef steers during adaptation to a high-concentrate 
diet. J. Anim. Sci. 70:2950–2958.
Gibb, D. J., M. Streeter, K. S. Schwartzkopf-Gensweing, and T. A. 
McAllister. 2008. Performance and bunk attendance of cattle fed 
steam-rolled or ground corn supplemented with laidlomycin and 
chrlortetracycline or monensin and tylosin. Can. J. Anim. Sci. 
88:499–506. doi:10.4141/CJAS07069
Glenny, A. M., D. G. Altman, F. Song, C. Sakarovitch, J. J. Deeks, 
R. D’Amico, M. Bradburn, and A. J. Eastwood. 2005. Indirect 
comparisons of competing interventions. Health Technol. 
Assess. 9:1–134. doi:10.3310/hta9260.
Higgins, J. P., and S. Green, editors. 2011. Cochrane handbook 
for systematic reviews of interventions. Version 5.1.0. The 
Cochrane Collaboration. http://www.cochrane-handbook.org. 
(Accessed 26 June 2015.)
Higgins, J. P., and S. G. Thompson. 2004. Controlling the risk of 
spurious findings from meta-regression. Stat. Med. 23:1663–
1682. doi:10.1002/sim.1752.
Higgins, J. P., S. G. Thompson, J. J. Deeks, and D. G. Altman. 
2003. Measuring inconsistency in meta-analyses. BMJ 
327:557–560. doi:10.1136/bmj.327.7414.557.
Jansen, J. P., R. Fleurence, B. Devine, R. Itzler, A. Barrett, N. 
Hawkins, K. Lee, C. Boersma, L. Annemans, and J. C. 
Cappelleri. 2011. Interpreting indirect treatment comparisons 
and network meta-analysis for health-care decision making: 
Report of the ISPOR task force on indirect treatment compar-
isons good research practices: Part 1. Value Health 14:417–
428. doi:10.1016/j.jval.2011.04.002.
Kreikemeier, K. K. 1997. Comparison of laidlomycin propionate 
and monensin at equal feed intakes. Cattle Feeders’ Day. 
Report of Progress 794. Kansas State University, Agricultural 
Experiment Station and Cooperative Extension Service. 
Southwest Research-Extension Center. http://www.asi.k-
state.edu/species/beef/research-and-extension/1997CFD.pdf 
(Accessed 23 March 2015.) p. 7–11.
Lean, I. J., A. R. Rabiee, T. F. Duffield, and I. R. Dohoo. 2009. 
Invited review: Use of meta-analysis in animal health and re-
production: Methods and applications. J. Dairy Sci. 92:3545–
3565. doi:10.3168/jds.2009-2140.
Cernicchiaro et al.1676
Mederos, A., L. Waddell, J. Sanchez, D. Kelton, A. S. Peregrine, 
P. Menzies, J. VanLeeuwen, and A. Rajic. 2012. A systematic 
review-meta-analysis of primary research investigating the 
effect of selected alternative treatments on gastrointestinal 
nematodes in sheep under filed conditions. Prev. Vet. Med. 
104:1–14. doi:10.1016/j.prevetmed.2011.10.012.
Nagaraja, T. G., and M. M. Chengappa. 1998. Liver abscesses in 
feedlot cattle: A review. J. Anim. Sci. 23:351–369.
O’Connor, A. M., K. M. Anderson, C. K. Goodell, and J. M. 
Sargeant. 2014a. Conducting systematic reviews of interven-
tion questions I: Writing the review protocol, formulating the 
question and searching the literature. Zoonoses Public Health 
61:28–38. doi:10.1111/zph.12125.
O’Connor, A. M., J. M. Sargeant, and C. Wang. 2014b. Conducting 
systematic reviews of intervention questions III: Synthetizing 
data from intervention studies using meta-analysis. Zoonoses 
Public Health 61:52–63. doi:10.1111/zph.12123.
Russell, J. B., and H. J. Strobel. 1989. Effect of ionophores on ruminal 
fermentation. Appl. Environ. Microbiol. 55:1–6. 
Sargeant, J. M., D. F. Kelton, and A. M. O’Connor. 2014a. 
Randomized controlled trials and challenge trials: Design 
and criterion for validity. Zoonoses Public Health 61:18–27. 
doi:10.1111/zph.12126.
Sargeant, J. M., D. F. Kelton, and A. M. O’Connor. 2014b. Study 
designs and systematic reviews of interventions: Building ev-
idence across study designs. Zoonoses Public Health 61:10–
17. doi:10.1111/zph.12127.
Song, F., I. Harvey, and R. Lilford. 2008. Adjusted indirect com-
parison may be less biased than direct comparison for evalu-
ating new pharmaceutical interventions. J. Clin. Epidemiol. 
61:455–463. doi:10.1016/j.jclinepi.2007.06.006.
Takeshima, N., T. Sozu, A. Tajika, Y. Ogawa, Y. Hayasaka, and T. 
A. Furukawa. 2014. Which is more generalizable, powerful 
and interpretable in meta-analyses, mean difference or stan-
dardized mean difference? BMC Med. Res. Methodol. 14:30. 
doi:10.1186/1471-2288-14-30.
USDA. Feedlot 2011. Part III: Trends in health and management 
practices on U.S. feedlots, 1994–2011. https://www.aphis.usda.
gov/animal_health/nahms/feedlot/downloads/feedlot2011/
Feed11_dr_Part%20III.pdf. (Accessed 26 June 2015.)
U.S. Food and Drug Administration (FDA). 2015a. Animal and 
veterinary drug products. NADA 141-025 Cattlyst® – original 
approval. http://www.fda.gov/AnimalVeterinary/Products/
ApprovedAnimalDrugProducts/FOIADrugSummaries/
ucm132769.htm (Accessed 26 June 2015.)
U.S. Food and Drug Administration (FDA) 2015b. NADA 
095-735 Rumensin - supplemental approval (October 22, 
1990). http://www.fda.gov/AnimalVeterinary/Products/
ApprovedAnimalDrugProducts/FOIADrugSummaries/
ucm064811.htm. (Accessed 26 June 2015).
Vogel, G. 1995. The effect of ionophores on feed intake by feedlot 
cattle. Lilly Research Laboratories, Canyon, TX.
